1.Regional clinical pharmacology trials for Multi-Regional clinical trials
Translational and Clinical Pharmacology 2018;26(3):101-102
No abstract available.
Pharmacology, Clinical
2.Translational and Clinical Pharmacology: Note from the new Editor-in-Chief
Translational and Clinical Pharmacology 2019;27(1):1-1
No abstract available.
Pharmacology, Clinical
3.Significance of Clinical Pharmacology in Pediatrics.
Journal of the Korean Pediatric Society 1997;40(11):1495-1500
No abstract available.
Pediatrics*
;
Pharmacology, Clinical*
4.History of clinical pharmacology in Korea.
Translational and Clinical Pharmacology 2014;22(2):43-51
No abstract available.
Korea
;
Pharmacology, Clinical*
5.Different relationships of pharmacists in clinical pharmacology in hospital
Pharmaceutical Journal 1999;370(8):5-8
The relationships between medical doctors and pharmacist play an important role. Because clinical information will not be discussed and exchanged if there is no cooperation between them. The clinical pharmacists relate with inpatients and outpatients. Otherwise, they have relations with nurse, sister, laboratories and other technician
Pharmacists
;
Pharmacology, Clinical
6.How a VOICE for clinical pharmacology turns into a RECIPE for its development.
Translational and Clinical Pharmacology 2016;24(1):1-6
Pharmacology is the study of the actions of synthetic or semisynthetic chemicals or naturally occurring substances on molecules, cells, tissues, and living organisms, as seen in physiological and pathological systems, seeking to establish order, pattern, and sequence among them, aiming ultimately to determine the rules by which pathophysiological information can be coded into molecules, allowing prediction of both beneficial and harmful consequences. Clinical pharmacology is the application, informed by an understanding of pharmacology, of all aspects of the study and use of medicines in humans, whose practitioners, normally medically qualified, teach, do research, frame policy, and give information and advice about the actions and proper uses of medicines in humans and implement that knowledge in clinical practice. Clinical pharmacology expanded in the UK during the 1960s and 1970s and maintained a steady state during the 1980s, but thereafter started to decline. Since 2006 this decline has been halted and partly reversed through the efforts of the British Pharmacological Society, by demonstrating the need for clinical pharmacology in clinical practice, teaching, research, and policy making, and bringing that need to the attention of medical colleagues, regulators, government, and the public. Efforts continue to maintain and enhance this recovery, using the VOICE paradigm, which involves improving and maintaining the Visibility of the specialty, Outreach to advertise its attractiveness to potential trainees and creating a public image for the specialty, Integration with other disciplines, encouraging Coverage of neglected areas, and the use of Emissaries, particularly younger members of the discipline, to promote it, both within medicine and in the wider world. Fortuitously, translation of the five elements of this paradigm into Korean, and back-translation into English, with the addition of a sixth element, provides a RECIPE for the future of clinical pharmacology and therapeutics.
Humans
;
Pharmacology
;
Pharmacology, Clinical*
;
Policy Making
;
Voice*
7.Mechanisms of the actions of interferons.
Chinese Journal of Hepatology 2007;15(11):845-846
8.Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy.
Translational and Clinical Pharmacology 2016;24(1):7-12
During the past two years, three immune checkpoint inhibitors, ipilimumab, nivolumab and pembrolizumab, have been approved and revolutionized cancer immunotherapy. Translational and clinical pharmacology of these agents have contributed in identifying patients who will receive benefit, dose effect relationship and surrogate endpoints of clinical benefit. In addition, population pharmacokinetics/pharmacodynamics have facilitated scientific clinical development, which has led to accelerated approval of these agents. This paradigm may show how early phase studies may allow identification of subgroup of patients who can benefit and subsequent approval of drugs based on smaller patient population. This may speed the access of effective treatment for patients with life-threatening diseases.
Biomarkers
;
Humans
;
Immunotherapy
;
Pharmacokinetics
;
Pharmacology, Clinical
9.Development Measures of the Journal of Korean Society for Clinical Pharmacology and Therapeutics.
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):5-16
The Journal of Korean Society for Clinical Pharmacology and Therapeutics (JKSCPT) as a peer-reviewed semi-annual journal has published lots of clinical pharmacology articles of various fields since its first issue in May 1993. Particularly, a number of high-quality articles such as randomized controlled prospective clinical trials have been presented in this journal. The JKSCPT currently has been also indexed in Scopus, one of the famous international bibliographic databases, and the candidate journal accredited by the National Research Foundation of Korea. Although the JKSCPT has accumulated outstanding achievements as the specialized journal for clinical pharmacology in Korea, it is also true that there are many problems to be solved in order to be a more internationally recognized journal. The methods to analyze the status of a journal for the academic society were first suggested in this article. The SWOT analysis on the current status of the JKSCPT was done for establishing future development strategies. Making references to these analyzing methods of a journal and SWOT analysis, numerous problems and the suggestions for the development of the JKSCPT were presented in detail. The future model of the journal for the academic society was also briefly discussed.
Achievement
;
Databases, Bibliographic
;
Korea
;
Pharmacology, Clinical
10.Digital therapeutics and clinical pharmacology
Translational and Clinical Pharmacology 2019;27(1):6-11
Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx.
Delivery of Health Care
;
Drug Therapy
;
Pharmacology, Clinical